CCL2 and metabolic dysfunction-associated steatotic liver disease: In summary, the current study demonstrates that ccl2 and jun are key regulators in all three NAFLD phenotypes and lead to abnormal fatty acid metabolism and inflammatory response through activation of TNF, P53, NF-κB, chemokine, PPAR and TLR signaling pathways.